Brief: Fate Therapeutics Reports Publication of FT538 Preclinical Data
15/09/2021 13:07
Sept 15 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS ANNOUNCES PUBLICATION OF FT538
PRECLINICAL
DATA DEMONSTRATING ENHANCED SERIAL KILLING AND FUNCTIONAL
PERSISTENCE WITHOUT CYTOKINE SUPPORT
Source text for Eikon: ID:nGNX47pTT6
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview